-
公开(公告)号：US20190092856A1
公开(公告)日：2019-03-28
申请号：US16214891
申请日：2018-12-10
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos Almagro , William DuBell , Johan Fransson , Jose Pardinas , Gopalan Raghunathan
Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
-
公开(公告)号：US08999333B2
公开(公告)日：2015-04-07
申请号：US14230128
申请日：2014-03-31
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos Almagro , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
Abstract translation: 本发明涉及能够预防组织因子（凝血因子F3）信号传导但不干扰因子VII结合或FX与组织因子结合并且不延长凝血时间的抗体的人源化形式。 本发明的抗体可用于治疗相关细胞表达组织因子和组织因子信号传导的病症，例如肿瘤进展。
-
公开(公告)号：US20170145090A1
公开(公告)日：2017-05-25
申请号：US15423189
申请日：2017-02-02
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos Almagro , William DuBell , Johann Fransson , Jose Pardinas , Gopalan Raghunathan
IPC: C07K16/24
CPC classification number: C07K16/248 , A61K2039/505 , A61K2039/54 , C07H21/00 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/526 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12N15/09
Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
-
公开(公告)号：US09163083B2
公开(公告)日：2015-10-20
申请号：US14104520
申请日：2013-12-12
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos Almagro , William DuBell , Johan Fransson , Jose Pardinas , Gopalan Raghunathan
IPC: A61K39/395 , A61K39/00 , C07K16/00 , C07K16/24
CPC classification number: C07K16/248 , A61K2039/505 , A61K2039/54 , C07H21/00 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/526 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12N15/09
Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
Abstract translation: 能够中和制瘤素M生物功能的抗体和组合物可用于治疗与制瘤素M相关的疾病和病症，例如骨关节炎和特发性肺纤维化。
-
公开(公告)号：US08951525B2
公开(公告)日：2015-02-10
申请号：US13803887
申请日：2013-03-14
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos Almagro , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
IPC: A61K39/395 , C07K16/46 , C07K16/36 , C07K16/28 , A61K39/00
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
-
Patent Agency Ranking
公开(公告)号：US20160009798A1
公开(公告)日：2016-01-14
申请号：US14870774
申请日：2015-09-30
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos Almagro , William DuBell , Johann Fransson , Jose Pardinas , Gopalan Raghunathan
IPC: C07K16/24
CPC classification number: C07K16/248 , A61K2039/505 , A61K2039/54 , C07H21/00 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/526 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12N15/09
Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
Abstract translation: 能够中和制瘤素M生物功能的抗体和组合物可用于治疗与制瘤素M相关的疾病和病症，例如骨关节炎和特发性肺纤维化。
-
7.发明授权公开(公告)号：US10179812B2
公开(公告)日：2019-01-15
申请号：US15423189
申请日：2017-02-02
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos Almagro , William DuBell , Johann Fransson , Jose Pardinas , Gopalan Raghunathan
IPC: A61K39/395 , C07K16/24 , C07H21/00 , C12N15/09 , A61K39/00
Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
-
公开(公告)号：US20140234304A1
公开(公告)日：2014-08-21
申请号：US14230128
申请日：2014-03-31
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos ALMAGRO , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
IPC: C07K16/40
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
Abstract translation: 本发明涉及能够预防组织因子（凝血因子F3）信号传导但不干扰因子VII结合或FX与组织因子结合并且不延长凝血时间的抗体的人源化形式。 本发明的抗体可用于治疗相关细胞表达组织因子和组织因子信号传导的病症，例如肿瘤进展。
-
公开(公告)号：US20140099315A1
公开(公告)日：2014-04-10
申请号：US14104520
申请日：2013-12-12
Applicant: JANSSEN BIOTECH, INC.
Inventor： Juan Carlos Almagro , William DuBell , Johan Fransson , Jose Pardinas , Gopalan Raghunathan
IPC: C07K16/24
CPC classification number: C07K16/248 , A61K2039/505 , A61K2039/54 , C07H21/00 , C07K2317/14 , C07K2317/21 , C07K2317/33 , C07K2317/526 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12N15/09
Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
Abstract translation: 能够中和制瘤素M生物功能的抗体和组合物可用于治疗与制瘤素M相关的疾病和病症，例如骨关节炎和特发性肺纤维化。
-
公开(公告)号：US10941197B2
公开(公告)日：2021-03-09
申请号：US16214891
申请日：2018-12-10
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos Almagro , William DuBell , Johan Fransson , Jose Pardinas , Gopalan Raghunathan
IPC: A61K39/395 , C07K16/24 , C07H21/00 , C12N15/09 , A61K39/00
Abstract: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.02 seconds)
